Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
FDA Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma
March 1st 2022The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Read More
Frontline Maintenance Avelumab Shows Consistent OS Benefit in Advanced Urothelial Cancer
February 18th 2022The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.
Read More
Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC
February 17th 2022Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.
Read More
UCSF Showcases Potentially Game-Changing Trials Across Multiple Myeloma Settings
February 14th 2022Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.
Read More
Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance
February 7th 2022Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.
Read More
Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers
January 28th 2022Arpita Gandhi, MD, discusses the background of Orca-T in further detail and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.
Read More
R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.
Read More
Trastuzumab Deruxtecan Upholds 40% Improvement in OS in HER2+ Advanced Gastric/GEJ Cancer
January 20th 2022Fam-trastuzumab deruxtecan-nxki demonstrated a 40% reduction in the risk of death compared with standard chemotherapy in patients with HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Read More
FDA Grants Fast Track Status to CYNK-001 for AML
December 27th 2021The FDA has granted Fast Track Designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the potential treatment of patients with acute myeloid leukemia.
Read More
FDA Approves TLX591-CDx for Prostate Cancer Imaging
December 20th 2021The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.
Read More
Pacritinib Shows Manageable Safety Profile in Cytopenic Myelofibrosis, Severe Thrombocytopenia
December 14th 2021Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.
Read More
Luspatercept Shows Impressive Responses, Tolerability in Low-Risk MDS
December 14th 2021Luspatercept-aamt produced more durable responses compared with placebo in patients with lower-risk myelodysplastic syndrome and anemia that is refractory to or ineligible for erythropoiesis-stimulating agent therapy.
Read More
Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL
December 13th 2021Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.
Read More
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
December 12th 2021Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Read More
Orca-T Shows Impressive Clinical Outcomes in High-Risk Hematological Cancers
December 11th 2021Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies
Read More
ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data
December 9th 2021Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.
Read More
Entinostat/Exemestane Improves PFS in Chinese Patients With Advanced HR+ Breast Cancer
December 7th 2021The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.
Read More
Elacestrant Significantly Improves PFS in Advanced ER+ Breast Cancer, Including ESR1-Mutant Subtype
December 7th 2021The selective estrogen receptor degrader elacestrant (RAD1901) led to a 30% reduction in the risk of disease progression or death compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibition.
Read More
FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia
November 30th 2021The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.
Read More
FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL
November 30th 2021The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.
Read More